FDA Approves SYFOVRE™ (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Visual Impairment in Senior Adults Apellis Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved SYFOVRE™ (pegcetacoplan injection) 15mg/0.1mL, the first and only treatment for geographic atrophy (GA) secondary to age-related [Read More]
Category: Latest News
New Study Finds Higher Prevalence of Age-Related Macular Degeneration (AMD) Cases than Previously Determined and a High Degree of County Variation
A new study “The Prevalence of Age-Related Macular Degeneration in the United States In 2019” published in JAMA Ophthalmology, found that in 2019, there were an estimated 19.83 million Americans were living with some form of age-related macular degeneration (AMD) in 2019. This is an increase of approximately more than 2.75 times previous estimates (which used a more [Read More]
Join Us for a Free Webinar on the New Living Well With Low Vision
Are you living with vision loss and blindness, have a family member or loved one with vision loss, or work with individuals with vision loss? If you answered yes, please join us on November 16 from 6:00-6:45pm Eastern to: Understand what low vision is and how trusted information and resources can ease the burden of [Read More]
Susvimo implant for Wet AMD Voluntarily Recalled
Susvimo, previously called Port Delivery System with ranibizumab (Lucentis), was FDA-approved on October 21, 2021, for intravitreal use via ocular implant for the treatment of people with wet (neovascular) age-related macular degeneration (AMD). Now, one year later, Genentech has announced that it is voluntarily recalling the implant and the insertion tool in the U.S. As [Read More]
Does VUITY™ Treat AMD?
A new drug called VUITY™ (pilocarpine hydrochloride ophthalmic solution) has recently gained attention as an eye drop that can improve near (close up) vision in individuals over 40. It does not, however, change the condition of the retina. The drug, made by Allergan, works as advertised, but it should not be expected to treat age-related [Read More]